Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Phanes Therapeutics reports its first patient has been administered with PT217 in a Phase 1 trial
Latest Hotspot
3 min read
Phanes Therapeutics reports its first patient has been administered with PT217 in a Phase 1 trial
13 September 2023
Biotech firm, Phanes Therapeutics, has announced its Phase 1 clinical trial of PT217, a first-in-class drug targeting DLL3 and CD47 in small cell lung cancer. The trial uses a new IgG-like bispecific antibody and the first patient has been treated.
Read →
An In-depth Analysis of Divalproex sodium's R&D Progress
Drug Insights
4 min read
An In-depth Analysis of Divalproex sodium's R&D Progress
13 September 2023
This article summarized the latest R&D progress of Divalproex sodium, the Mechanism of Action for Divalproex sodium, and the drug target R&D trends for Divalproex sodium.
Read →
Searching for Modified Sequences: The Best Biological Databases to Consider
Bio Sequence
2 min read
Searching for Modified Sequences: The Best Biological Databases to Consider
13 September 2023
Sequence modification is an important attribute of a sequence, particularly in the field of small nucleic acids. Sequence modifications, including fluorescence labeling, glycosylation, phosphorylation, and others, can enhance the functionality of a sequence, making them highly meaningful. In the Patsnap Bio Sequence Database, you can search for modified sequences.
Read →
 Desonide: Detailed Review of its Transformative R&D Success, Mechanism of Action
Drug Insights
4 min read
Desonide: Detailed Review of its Transformative R&D Success, Mechanism of Action
13 September 2023
This article summarized the latest R&D progress of Desonide, the Mechanism of Action for Desonide, and the drug target R&D trends for Desonide.
Read →
Seladelpar from CymaBay Reaches Significant Statistical Levels for primary and key Secondary endpoints in the RESPONSE Phase 3 Trial
Latest Hotspot
4 min read
Seladelpar from CymaBay Reaches Significant Statistical Levels for primary and key Secondary endpoints in the RESPONSE Phase 3 Trial
13 September 2023
Biotech firm CymaBay Therapeutics, Inc. revealed positive Phase 3 trial outcomes for seladelpar, a novel treatment for liver and chronic diseases, including primary biliary cholangitis. Meeting all primary and key secondary endpoints.
Read →
Clindamycin Phosphate Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs, Mechanisms of Action, and Drug Target
Drug Insights
4 min read
Clindamycin Phosphate Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs, Mechanisms of Action, and Drug Target
13 September 2023
This article summarized the latest R&D progress of Clindamycin Phosphate, the Mechanism of Action for Clindamycin Phosphate, and the drug target R&D trends for Clindamycin Phosphate.
Read →
JAK1 Inhibitor - A rising star of small molecule targeted drugs in the field of autoimmunity
JAK1 Inhibitor - A rising star of small molecule targeted drugs in the field of autoimmunity
13 September 2023
In autoimmune diseases, JAK inhibitors can mediate immune suppression and inhibit the increase of serum pro-inflammatory cytokines.
Read →
A Comprehensive Review of Cefuroxime Axetil's R&D Innovations and Drug Target Mechanism
Drug Insights
4 min read
A Comprehensive Review of Cefuroxime Axetil's R&D Innovations and Drug Target Mechanism
13 September 2023
This article summarized the latest R&D progress of Cefuroxime Axetil, the Mechanism of Action for Cefuroxime Axetil, and the drug target R&D trends for Cefuroxime Axetil.
Read →
Adrenomed presents novel results for their precision medicine therapy with enibarcimab for septic shock
Latest Hotspot
3 min read
Adrenomed presents novel results for their precision medicine therapy with enibarcimab for septic shock
13 September 2023
Adrenomed AG has disclosed recent discoveries regarding the biomarker-directed therapy of septic shock with enibarcimab.
Read →
Pharmaceutical Insights: Ceftazidime's R&D Progress and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Pharmaceutical Insights: Ceftazidime's R&D Progress and its Mechanism of Action on Drug Target
13 September 2023
This article summarized the latest R&D progress of Ceftazidime, the Mechanism of Action for Ceftazidime, and the drug target R&D trends for Ceftazidime.
Read →
The Research and Development Boom is Unstoppable-KRAS G12D Inhibitors
The Research and Development Boom is Unstoppable-KRAS G12D Inhibitors
12 September 2023
KRAS G12D differs from KRAS G12C only in the type of amino acid mutation on the same codon.
Read →
Exploring Cefadroxil's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Exploring Cefadroxil's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
12 September 2023
This article summarized the latest R&D progress of Cefadroxil, the Mechanism of Action for Cefadroxil, and the drug target R&D trends for Cefadroxil.
Read →